I suppose it’s possible President Obama could have come up with a more anti-market reform to deal with its concerns over higher health insurance rates, but short of creating a single-payer health system, creating a seven-member panel to dictate the prices of health insurance is pretty close.
Big pharmaceutical companies have been raising prices on a lot of drugs recently. Some critics say the industry's trying to cash in before government price controls possibly get put into place.
As someone who studies the way people perceive risk, and the importance of trust to those perceptions, it continues to amaze me how many smart successful firms like Toyota manage to forget the importance of trust until they’re in trouble, and then they have to spend huge amounts of money and effort, for years, trying to rebuild it, writes the author David Ropeik.
The stock market, being that discounting mechanism that it is, is not going to take this lightly, but instead treat this as a starting pistol to a difficult period of the removal of easy money for the markets, culminating in a hike of the Fed Funds rate.
A source tells CNBC that former President Bill Clinton received two drug-coated stents, called "Xience," made by Abbott Labs.
Washington’s new political reality has left the fate of comprehensive healthcare reform uncertain, but there’s still plenty Congress and the Obama administration can do to improve the American healthcare system, writes this CEO.
Lockstep with Boomer aging, established industries are about to grow exponentially, and new wealth will be created by enterprises yet to be conceived.
Suffice to say that diabetes is a huge and fast-growing problem and represents a huge and fast-growing drug and device market.
I’m kind of torn over the fact that I’ve decided I won’t be going to the annual American College of Cardiology meeting in Atlanta about a month from now.
If you're left-handed, bowl with your right, eat red licorice, but only on Sunday afternoons, are female under 24-and-a-half years old or male over 33-and-three-quarters and loved "Dances With Wolves," then our drug is now approved for you to take.
So far this year, the performance of the biotechnology index has been strong. So is there room for more growth in the sector? Mark Schoenebaum, managing director and senior research analyst at Deutsche Bank Securities shared his stock picks.
I don't buy into the silly conspiracy theories that global health authorities worked in cahoots with the big, bad drug companies to gin up a pandemic scare just to goose vaccine and flu drug sales. Try telling that to the family of someone who died from H1N1.
The big drug companies are all looking to increase their footprints in emerging markets like India. But a young Ph.D., top-talent employee at Bristol-Myers Squibb apparently wanted to plant the flag on his own in his native country.
Thirteen-grand a year. That's about how much Acorda Therapeutics says it'll charge for its newly approved drug Ampyra for multiple sclerosis.
With the health care reform in doubt, are some pharmaceutical stocks poised to pop? Les Funtleyder, health care strategist at Miller Tabak, discussed his best stock picks.
Nearly every city and state wants biopharma. They fiercely compete for the relatively clean industry and the well-paid, highly educated jobs it brings.
For Roche/Genentech the timing could not be worse. At a time when cutting healthcare costs could still end up being put back on the frontburner in Washington comes a study showing how to possibly save a heckuva lot of money.
Three out of four prescriptions in the U.S. are filled with generics. But a new, albeit small, survey by a prominent generic drug industry analyst shows even the people filling those pill bottles have issues with generics.
Markets opened mixed on Thursday. What should investors expect from stocks going forward? Ray Harrison, founder of Harrison Financial Group, and Bill Smead, CEO and CIO of Smead Capital Management, shared their investment plays.
Big pharma is in the middle of getting leaner and meaner. Most, if not all, of the majors are getting rid of employees. They need to cut costs to preserve profits in the face of tens of billions of dollars worth of brand-name drugs going generic and their pipelines not delivering enough to fill that void. It's a sad reality of the business.